

## AMENDMENTS TO THE CLAIMS

1-14. (Canceled).

15. (Previously Presented) A method for maintaining or improving the visual acuity and the field of vision in a patient in need of such treatment, said method comprising:

administering a drug comprising ramipril, wherein said drug maintains or improves visual acuity and the field of vision.

16. (Previously Presented) The method according to claim 15, wherein said drug is an ophthalmic neuro-protector and/or a retinoprotector.

17-20. (Canceled).

21. (Previously Presented) The method according to claim 15, wherein said drug is administered orally.

22. (Previously Presented) The method according to claim 21, wherein ramipril is administered at a dose of 0.5 to 5 mg/day.

23. (Previously Presented) The method according to claim 21, wherein ramipril is administered at a dose of 1 to 2 mg/day.

24. (Previously Presented) The method according to claim 21, wherein ramipril is administered at a dose of 1.25 mg/day.

25. (Previously Presented) The method according to claim 15, wherein said drug is administered parenterally.

26. (Previously Presented) The method according to claim 25, wherein said drug is administered intravenously or intramuscularly or transdermically or topically.

27. (Previously Presented) The method according to claim 26, wherein said drug is administered topically to the eye.

28. (Previously Presented) The method according to claim 27, wherein said drug is administered as an ophthalmic solution.

29. (Previously Presented) The method according to claim 15, wherein said patient has a degenerating chorioretinopathy or has an optic neuropathy or has both a

degenerating chorioretinopathy and an optic neuropathy.

30. (Previously Presented) The method according to claim 15, wherein said patient has a glaucomatous neuropathy.

31. (Previously Presented) The method according to claim 15, wherein said patient has a degenerative chorioretinopathy in severe myopia.

32. (Previously Presented) The method according to claim 15, wherein said patient has age-related macular degeneration with or without sub-retinal neovessels.

33. (Previously Presented) The method according to claim 15, wherein said patient has a central serous chorioretinopathy or a chronic central serous chorioretinopathy.

34. (Previously Presented) The method according to claim 15, wherein said patient has a hereditary dystrophy of the retina.

35. (Previously Presented) The method according to claim 34, wherein said hereditary dystrophy of the retina is a retinitis pigmentosa.

36. (Previously Presented) The method according to claim 15, wherein said patient has a retinal venous occlusion.

37. (Currently Amended) The method according to claim 15, wherein said patient is aged 60 years or older.

38. (Canceled).